Medizinische Klinik

, Volume 104, Issue 2, pp 125–136 | Cite as

Behandlung der Plaque-Psoriasis mit Biologics

Eine Metaanalyse randomisierter kontrollierter Studien
  • Zhengguang Zhang
  • Jochen Schmitt
  • Gottfried Wozel
  • Wilhelm Kirch
PRÄVENTION UND VERSORGUNGSFORSCHUNG

Zusammenfassung

Hintergrund und Ziel:

Die Entwicklung verschiedener biologischer Therapien (sog. Biologics) ist ein großer Fortschritt für die Behandlung der Psoriasis vulgaris. Diese Metaanalyse fasst die Evidenz aus randomisierten kontrollierten Studien (RCTs) der in Deutschland zur Behandlung der mittelschweren bis schweren Psoriasis vulgaris zugelassenen Biologics zusammen.

Material und Methodik:

Systematisches Review und Metaanalyse aller RCTs, in denen im Januar 2008 in Deutschland zur Behandlung der mittelschweren bis schweren Psoriasis vulgaris zugelassene Biologics geprüft wurden. Identifikation relevanter Studien durch systematische elektronische Literaturrecherche in MEDLINE, EMBASE, Cochrane Library und Scopus. Primärer Endpunkt: Anteil an Patienten mit mindestens 75%iger Reduktion im Psoriasis Area and Severity Index (PASI) Score (PASI75-Responder), sekundäre Endpunkte: klinisch relevante Besserung der Lebensqualität, monatliche Inzidenz an Studienabbrüchen und unerwünschten Ereignissen. Die Prozentsätze der PASI75-Responder wurden als Risikodifferenz (RD) dargestellt und statistisch zusammengefasst.

Ergebnisse:

25 Artikel zu 16 RCTs mit insgesamt 8 057 Patienten mit mittelschwerer bis schwerer Psoriasis vulgaris wurden qualitativ analysiert. 15 doppelblinde, plazebokontrollierte Studien wurden in die Metaanalyse eingeschlossen. Infliximab war wirksamer als alle anderen biologischen Optionen als Kurztherapie für die mittelschwere bis schwere Psoriasis vulgaris (RD [95%-Konfidenzintervall, CI] 76% [72–80%]). Adalimumab (RD [95%-CI] 59% [45–73%]) war wirksamer als Efalizumab (RD [95%-CI] 24% [19–30%]) und Etanercept. Bei Etanercept bestand ein deutlicher Dosis-Wirkungs-Effekt (2 × 50 mg wöchentlich: RD [95%-CI] 44% [40–48%]; 2 × 25 mg wöchentlich: RD [95%-CI] 30% [25–35%]). Die Behandlung mit allen untersuchten Biologics verbesserte die Lebensqualität der Psoriasispatienten. Die monatliche Rate an Studienabbrüchen aufgrund unerwünschter Ereignisse betrug bei Infliximab 1,2%, bei Etanercept 0,5%, bei Efalizumab 1,0% und bei Adalimumab 0,5%.

Schlussfolgerung:

Der klinische Nutzen der einzelnen derzeit zur Behandlung der mittelschweren bis schweren Psoriasis vulgaris zugelassenen Biologics unterscheidet sich beträchtlich. Infliximab ist die wirksamste Therapieoption, gefolgt von Adalimumab. Große kontrollierte Studien deuten auf eine hohe Sicherheit aller Präparate in der Kurzzeittherapie hin. Kürzlich etablierte Register werden weitere wichtige Daten zur Sicherheit unter Alltagsbedingungen liefern.

Schlüsselwörter:

Systematisches Review Metaanalyse Psoriasis vulgaris Efalizumab Etanercept Infliximab Adalimumab 

Treatment of Plaque Psoriasis with Biologics. A Meta-Analysis of Randomized Controlled Trials

Abstract

Background and Purpose:

The development of different biological therapies (so-called biologics) is a great progress for the treatment of the psoriasis vulgaris. The evidence from randomized controlled trials (RCTs) of biologics, which have been licensed in Germany for the treatment of moderate-to-severe psoriasis vulgaris, were pooled in this meta-analysis.

Material and Methods:

Systematic review and meta-analysis of all RCTs, in which biologics licensed in Germany as of January 2008 for the treatment of moderate-to-severe psoriasis vulgaris were examined. Relevant trials were identified by systematic electronic literature search in MEDLINE, EMBASE, Cochrane Library, and Scopus. Primary endpoint: proportion of patients achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI) Score (PASI75 responder), secondary endpoints: clinically relevant improvement in the quality of life, monthly incidences of study withdrawals and adverse events. PASI75 response rates were statistically pooled and represented as risk differences (RD).

Results:

25 articles on 16 RCTs totaling 8,057 patients with moderate-to-severe psoriasis vulgaris were qualitatively analyzed. 15 double-blind and placebo- controlled trials were compared by meta-analysis. Infliximab had the highest efficacy in the short-term therapy of moderate-to-severe psoriasis vulgaris (RD [95% confidence interval, CI] 76% [72–80%]). Adalimumab (RD [95% CI] 59% [45–73%]) was more effective than efalizumab (RD [95% CI] 24% (19–30%]) and etanercept. Treatment with etanercept showed a clear dose-response effect (50 mg twice weekly: RD [95% CI] 44% (40–48%]; 25 mg twice weekly: RD [95% CI] 30% (25–35%]). All biologics improved the quality of life of psoriasis patients. Monthly incidence rates of withdrawals due to adverse events were 1.2% for infliximab, 0.5% for etanercept, 1.0% for efalizumab, and 0.5% for adalimumab.

Conclusion:

A patient’s chance to reach considerable clinical benefit differs significantly between the different biological therapies currently approved for moderate-to-severe psoriasis vulgaris. Infliximab is most effective, followed by adalimumab. Large controlled studies indicate a high safety of all biologics in the short-term treatment. Recently established registers will provide additional important safety data under real-life conditions.

Key Words:

Systematic review Meta-analysis Psoriasis vulgaris Efalizumab Etanercept Infliximab Adalimumab 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Nast A, Kopp IB, Augustin M, et al. [S3-guidelines for the therapy of psoriasis vulgaris.] J Dtsch Dermatol Ges 2006;4:Suppl 2:S1–126.PubMedGoogle Scholar
  2. 2.
    Feldman SR, Fleischer ABJr, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Schmitt J, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006;213:102–10.PubMedCrossRefGoogle Scholar
  4. 4.
    Sohn S, Schoeffski O, Prinz J, et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 2006;212:137–44.PubMedCrossRefGoogle Scholar
  5. 5.
    Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007;215:17–27.PubMedCrossRefGoogle Scholar
  8. 8.
    Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007;5:566–74.PubMedCrossRefGoogle Scholar
  9. 9.
    Wozel G, Jahn S, Hrsg. Biologics in der Dermatologie, 2. Aufl. Bremen-London-Boston: Uni-Med, 2006.Google Scholar
  10. 10.
    Claes C, Kulp W, Greiner W, et al. Therapie der mittelschweren und der schweren Psoriasis. GMS Health Technol Assess 2006;2:Doc07.Google Scholar
  11. 11.
    Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1–125.PubMedGoogle Scholar
  12. 12.
    Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46).Google Scholar
  13. 13.
    Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Shikiar R, Bresnahan BW, Stone SP, et al. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003;1:53.PubMedCrossRefGoogle Scholar
  15. 15.
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Egger M, Smith GD, Altman DG. Systematic reviews in health care. Meta-analysis in context. London: BMJ, 2003.Google Scholar
  18. 18.
    Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 2005;152:954–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367–74.PubMedCrossRefGoogle Scholar
  22. 22.
    Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 2006;154:1161–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31.e1–15.PubMedGoogle Scholar
  24. 24.
    Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–22.PubMedCrossRefGoogle Scholar
  25. 25.
    Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53: 887–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12.PubMedCrossRefGoogle Scholar
  28. 28.
    Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 2005;153:1192–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719–26.PubMedCrossRefGoogle Scholar
  31. 31.
    Cassano N, Loconsole F, Galluccio A, et al. Once-weekly administration of high-dosage etanercept in patients with plaque psoriasis: results of a pilot experience (power study). Int J Immunopathol Pharmacol 2006;19:225–9.PubMedGoogle Scholar
  32. 32.
    Gordon KB, Papp KA, Hamilton TK, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003;290:3073–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Menter A, Gordon K, Carey W, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004–13.PubMedCrossRefGoogle Scholar
  35. 35.
    Leonardi CL, Papp KA, Gordon KB, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425–33.PubMedCrossRefGoogle Scholar
  36. 36.
    Papp KA, Bressinck R, Fretzin S, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol 2006;45:605–14.PubMedCrossRefGoogle Scholar
  37. 37.
    Dubertret L, Sterry W, Bos JD, et al. Clinical Experience Acquired with the Efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170–81.PubMedCrossRefGoogle Scholar
  38. 38.
    Ortonne JP, Shear N, Shumack S, et al. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol 2005;5:13.PubMedCrossRefGoogle Scholar
  39. 39.
    Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598–606.PubMedCrossRefGoogle Scholar
  40. 40.
    Shikiar R, Willian MK, Okun MM, et al. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes 2006;4:71.PubMedCrossRefGoogle Scholar
  41. 41.
    Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatol Treat 2007;18:25–31.CrossRefGoogle Scholar
  42. 42.
    Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106–15.PubMedCrossRefGoogle Scholar
  43. 43.
    Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558–66.PubMedCrossRefGoogle Scholar
  44. 44.
    Paller AS, Paller AS, Siegfried EC, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358:241–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152:861–7.PubMedCrossRefGoogle Scholar
  47. 47.
    Naldi L. The search for effective and safe disease control in psoriasis. Lancet 2008;371:1311–2.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel, Muenchen 2009

Authors and Affiliations

  • Zhengguang Zhang
    • 1
    • 3
  • Jochen Schmitt
    • 2
  • Gottfried Wozel
    • 2
  • Wilhelm Kirch
    • 1
  1. 1.Institut für Klinische Pharmakologie, Medizinische Fakultät „Carl Gustav Carus“Technische Universität DresdenDresdenGermany
  2. 2.Klinik und Poliklinik für Dermatologie, Medizinische Fakultät „Carl Gustav Carus“Technische Universität DresdenDresdenGermany
  3. 3.Institut für Klinische Pharmakologie, Medizinische Fakultät „Carl Gustav Carus“Technische Universität DresdenDresdenGermany

Personalised recommendations